Novartis Advances $12 Billion Acquisition of Avidity Biosciences for RNA Therapeutics Platform
核心洞察
Novartis is proceeding with a $12 billion acquisition of Avidity Biosciences (搜索) at $72 per share, with shareholder voting scheduled for February 23, 2026.
The deal centers on Avidity's proprietary AOC platform (搜索) for delivering RNA-based therapies to muscle tissue (搜索) and its promising del-zota treatment for Duchenne muscular dystrophy (搜索).
Avidity reported positive EXPLORE44 study results for del-zota and plans to submit its first Biologics License Application in Q1 2026.
Swiss pharmaceutical giant Novartis is moving forward with its landmark $12 billion acquisition of biotechnology company Avidity Biosciences (搜索), with definitive proxy materials released and a shareholder vote scheduled for February 23, 2026. The all-cash transaction, valued at $72.00 per share, has received unanimous board approval and represents a strategic expansion of Novartis's neuroscience portfolio.
Strategic Focus on RNA Therapeutics Platform
The acquisition is driven by Novartis's interest in Avidity's proprietary AOC (Antibody Oligonucleotide Conjugates) platform, which is designed to deliver RNA-based therapies directly into muscle tissue (搜索). Novartis plans to integrate this technology with its existing neuroscience portfolio to advance more precise genetic medicines.
The deal structure includes a strategic spin-off of Avidity's early-stage precision cardiology research programs into a new independent entity named Atrium Therapeutics (搜索). Shareholders will receive one share of Atrium Therapeutics for every ten Avidity shares they hold, preserving potential value from the cardiology pipeline for existing investors while allowing Novartis to focus on the core neuromuscular RNA therapeutics platform.
Clinical Progress Drives Valuation
Avidity's development pipeline has demonstrated significant progress, particularly with del-zota, a treatment for Duchenne muscular dystrophy (搜索) (DMD44). The company recently reported positive topline results from its EXPLORE44 studies, showing clinically meaningful improvements after approximately one year of treatment.
Following a pre-BLA meeting, the U.S. Food and Drug Administration has provided a clear regulatory pathway for del-zota. Avidity is preparing its first Biologics License Application (BLA) submission for the first quarter of 2026, which would initiate a series of three planned regulatory filings within a twelve-month period.
Financial Performance and Market Response
Avidity's third quarter 2025 financial results reflected the typical biotech profile of promising science alongside developmental-stage economics. Revenue surged to $12.48 million, vastly exceeding expectations and representing growth of over 420% year-over-year. However, the quarterly loss per share of ($1.27) missed analyst estimates, underscoring the distance to future profitability that is standard for companies at this development stage.
The $72.00 per share acquisition offer has created a definitive ceiling for Avidity's stock price, prompting several research firms to adjust their ratings. Chardan Capital Markets downgraded from "Buy" to "Neutral" with a $72.00 price target, while TD Cowen moved to "Hold" and lowered its target from $78.00 to $74.00. RBC Capital shifted from "Outperform" to "Sector Perform," raising its target from $61.00 to $72.00.
Transaction Timeline and Insider Activity
Final approval of the acquisition is anticipated in the first half of 2026, contingent on the favorable shareholder vote in February. The company is scheduled to report quarterly earnings on February 26, 2026, just three days after the pivotal vote, which will provide operational details ahead of the anticipated ownership transition.
Company insider transactions have reflected anticipation of the deal's closure. Chief Executive Officer Sarah Boyce sold 50,000 shares on September 5 at an average price of $49.95, while insider Eric Mosbrooker disposed of 6,562 shares on October 3 at $45.38 per share. These sales are widely interpreted as profit-taking in anticipation of the deal's completion.
The stock has been trading within a narrow band dictated by the pending acquisition terms, with shares gaining 0.266% in the previous session to close at $71.54. Trading volume of 2 million shares indicates continued investor interest as the market awaits final closure of the transaction.